Osteoporosis: Global Drug Forecast and Market Analysis to 2027
Global Osteoporosis pharmaceutical market in 2017 was $7.4B, including both branded and generic products. The branded market accounted for $3.4B in sales. As such, osteoporosis remains a highly genericized market dominated by the sales of generic bisphosphates, which accounted for 41% of the global market in 2017.
Despite being a market currently monopolized by generics, osteoporosis is expected to undergo substantial change between 2017 and 2027. Clear changes are already being seen with the recent launch of Radius Health’s Tymlos (abaloparatide) in the US in 2017. Anabolic agents are likely to further revolutionize the market with the arrival of a novel sclerostin inhibitor, Evenity (romosozumab), and teriparatide biosimilars. This diversification of the anabolic offering will increase competition in this space, driving down high price tags and potentially bolstering the use of these therapies up the treatment paradigm.
Even with multiple classes of therapy options and a well-established treatment paradigm, there still remains high unmet need with in the osteoporosis market. A major outstanding need is the low rate of diagnosis and treatment. A further need is the continued concern around the safety profiles of treatment options and the long-term use of therapies. The need to reduce the burden of prolonged treatment in this chronic disease is abundantly clear and is unlikely to be met by the current state of the pipeline.
Furthermore, there is a desire for a therapy that can combine an improved safety profile with a novel mechanism of action, which can provide a stronger efficacy than current therapies. Such a therapy should go above and beyond that of current prescriber favorite, bisphosphates, and provide an option that not only prevents bone resorption but also stimulates bone formation.
The arrival of new anabolic agents and the loss of patent protection for key branded therapies will shape the osteoporosis market over the forecast period. However, poor diagnosis rates, badly perceived drug side effects, and low compliance rates will continue to prove major barriers to growth over the next 10 years.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook